Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment
Tango Therapeutics and Erasca began a Phase I/II trial for ERAS-0015 and vopimetostat combo in lung and pancreatic cancer patients. The trial, sponsored by Tango, aims to find the max tolerated dose and assess safety, tolerability, and antitumour activity. Both companies believe the combo shows promise in treating RAS-driven cancers. ERAS-0015 targets RAS signalling, while vopimetostat inhibits PRMT5.
How this was made
The 30-second read
Why it matters
The trial start signals progress for both companies' pipelines but provides no immediate financial impact. Investors may watch for future data releases.
Market read
Early‑stage clinical trial initiation; limited immediate market effect but potential long‑term relevance for oncology biotech sector.
What to watch
Potential competition in RAS‑targeted therapies and regulatory timelines.
Background
Tango Therapeutics and Erasca have opened enrolment for a Phase I/II trial of their combined oral therapies ERAS-0015 and vopimetostat in MTAP‑deleted pancreatic and RAS‑mutant lung cancers.
Market effects
None
None
None
Counterpoint
No clear contrarian angle; early trial data could be delayed or negative.
Key entities
- companyTango Therapeutics
Biotech firm developing the PRMT5 inhibitor vopimetostat.
- companyErasca
Biotech firm developing the pan‑RAS molecular glue ERAS‑0015.


